- Home
- GLRE vs OCGN Comparison
GLRE vs OCGN Comparison
Compare GLRE & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | OCGN |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.7M | 474.8M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLRE | OCGN |
|---|---|---|
| Price | $14.83 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.17 |
| AVG Volume (30 Days) | 117.3K | ★ 8.7M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | $12.33 |
| Revenue Next Year | N/A | $10.95 |
| P/E Ratio | $81.89 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $0.97 |
| 52 Week High | $19.39 | $2.73 |
Technical Indicators
Market Signals| Indicator | GLRE | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 43.00 |
| Support Level | $14.62 | $0.97 |
| Resistance Level | $15.31 | $1.93 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.75 | 53.07 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").